Belite Bio, Inc (BLTE)
NEGATIVEファンダメンタル
~26
株価
$160.80
時価総額
$6.44B
パート1 · 企業の価値
概要
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
利用可能な財務データが限定的です（指標の33%）。スコアはこの企業のファンダメンタルズを正確に反映していない場合があります。
貸借対照表と流動性
売上高
0
2025/12/31に終了した会計年度
純利益
$-78M
2025/12/31に終了した会計年度
フリーキャッシュフロー
-
自己資本合計
$777M
負債合計
0
流動比率
33.56
利払い倍率
-
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$214.00
現在株価
$160.80
安全マージン
+24.9%
適正価値レンジ
$203.30 - $224.70
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-22.1%
P/B レシオ
8.11
P/FCF
-
粗利益率
0.0%
ROIC
-
収益性レーダー
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
ファンダメンタル分析基準
合格（3）
- Price CAGR 52.03%
- Current Ratio
- Analyst Consensus 93% Buy
不合格（6）
- Gross Margin 0.0%
- P/B Ratio 8.11
- DCF valuation (Unknown)
- ROE -26.9%
- Earnings Surprise avg -19.7%
- Piotroski F-Score 0/9
データなし（18）
- EPS data insufficient
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
- Net Margin Trend (invalid data)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | 47 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | 41 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 59 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 56 |
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for BLTE, sourced from Markets Gazette.
- 3/3/2026NEUTRALBelite Bio (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio (BLTE) investors are awaiting crucial details following the announcement of the Q4 2025 earnings call transcript. Although the event was reported, the actual content of the transcript is not yet available. This lack of information prevents analysts and investors from assessing the company's financial performance, future outlook, or any significant announcements that could impact the stock's value. Transparency is key for the market, and the absence of concrete data keeps the stock in a phase of uncertainty, with operators eagerly awaiting details to formulate forecasts and make informed decisions.
via Markets Gazette